Medpace Hldgs Analyst Ratings
Medpace Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 17.48% | Baird | $270 → $289 | Upgrades | Neutral → Outperform |
| 07/25/2023 | 10.98% | Guggenheim | $252 → $273 | Maintains | Buy |
| 05/08/2023 | 2.44% | Guggenheim | → $252 | Upgrades | Neutral → Buy |
| 02/15/2023 | -5.28% | Baird | $226 → $233 | Maintains | Neutral |
| 10/27/2022 | — | UBS | Upgrades | Sell → Neutral | |
| 10/26/2022 | -11.79% | Baird | $200 → $217 | Maintains | Neutral |
| 09/07/2022 | -42.28% | UBS | → $142 | Initiates Coverage On | → Sell |
| 05/24/2022 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 07/20/2021 | -16.67% | Credit Suisse | $200 → $205 | Maintains | Outperform |
| 03/17/2021 | -26.42% | Credit Suisse | $178 → $181 | Maintains | Outperform |
| 02/17/2021 | -26.83% | Truist Securities | $135 → $180 | Maintains | Buy |
| 02/16/2021 | -27.64% | Credit Suisse | $155 → $178 | Maintains | Outperform |
| 10/02/2020 | -45.12% | Truist Securities | $124 → $135 | Upgrades | Hold → Buy |
| 07/28/2020 | -53.66% | Credit Suisse | $92 → $114 | Maintains | Outperform |
| 06/08/2020 | -66.26% | Baird | → $83 | Upgrades | Underperform → Neutral |
| 04/30/2020 | -65.45% | SunTrust Robinson Humphrey | $54 → $85 | Upgrades | Sell → Hold |
| 04/29/2020 | -62.6% | Credit Suisse | $105 → $92 | Maintains | Outperform |
| 04/20/2020 | -68.7% | Baird | → $77 | Downgrades | Neutral → Underperform |
| 04/06/2020 | -78.05% | SunTrust Robinson Humphrey | $46 → $54 | Maintains | Sell |
| 03/23/2020 | -69.51% | Jefferies | $93 → $75 | Maintains | Hold |
| 03/17/2020 | -81.3% | SunTrust Robinson Humphrey | $100 → $46 | Downgrades | Hold → Sell |
| 02/25/2020 | -59.76% | Credit Suisse | $91 → $99 | Maintains | Outperform |
| 01/27/2020 | -64.63% | SunTrust Robinson Humphrey | $85 → $87 | Downgrades | Buy → Hold |
| 04/30/2019 | -74.8% | Baird | $57 → $62 | Maintains | Neutral |
| 10/31/2018 | — | SunTrust Robinson Humphrey | Upgrades | Hold → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月24日 | 17.48% | 贝尔德 | $270→$289 | 升级 | 中性→表现优异 |
| 07/25/2023 | 10.98% | 古根海姆 | $252→$273 | 维护 | 买 |
| 05/08/2023 | 2.44% | 古根海姆 | →$252 | 升级 | 中性→购买 |
| 02/15/2023 | -5.28% | 贝尔德 | $226→$233 | 维护 | 中性 |
| 10/27/2022 | - | 瑞银集团 | 升级 | 卖出→中性 | |
| 10/26/2022 | -11.79% | 贝尔德 | $200→$217 | 维护 | 中性 |
| 09/07/2022 | -42.28% | 瑞银集团 | →$142 | 开始承保 | →销售 |
| 2022年05月24日 | - | 古根海姆 | 开始承保 | →中性 | |
| 07/20/2021 | -16.67% | 瑞士信贷 | $200→$205 | 维护 | 跑赢大盘 |
| 03/17/2021 | -26.42% | 瑞士信贷 | $178→$181 | 维护 | 跑赢大盘 |
| 02/17/2021 | -26.83% | Truist证券 | $135→$180 | 维护 | 买 |
| 02/16/2021 | -27.64% | 瑞士信贷 | $155→$178 | 维护 | 跑赢大盘 |
| 10/02/2020 | -45.12% | Truist证券 | $124→$135 | 升级 | 持有→购买 |
| 07/28/2020 | -53.66% | 瑞士信贷 | $92→$114 | 维护 | 跑赢大盘 |
| 06/08/2020 | -66.26% | 贝尔德 | →$83 | 升级 | 表现不佳的→中性 |
| 04/30/2020 | -65.45% | SunTrust Robinson Humphrey | $54→$85 | 升级 | 销售→Hold |
| 04/29/2020 | -62.6% | 瑞士信贷 | $105→$92 | 维护 | 跑赢大盘 |
| 04/20/2020 | -68.7% | 贝尔德 | →$77 | 评级下调 | 中性→表现不佳 |
| 04/06/2020 | -78.05% | SunTrust Robinson Humphrey | $46→$54 | 维护 | 卖 |
| 03/23/2020 | -69.51% | 杰富瑞 | $93→$75 | 维护 | 保持 |
| 03/17/2020 | -81.3% | SunTrust Robinson Humphrey | $100→$46 | 评级下调 | 持有→Sell |
| 02/25/2020 | -59.76% | 瑞士信贷 | $91→$99 | 维护 | 跑赢大盘 |
| 2020/01/27 | -64.63% | SunTrust Robinson Humphrey | $85→$87 | 评级下调 | 购买→Hold |
| 2019年04月30日 | -74.8% | 贝尔德 | $57→$62 | 维护 | 中性 |
| 2018年10月31日 | - | SunTrust Robinson Humphrey | 升级 | 持有→购买 |
What is the target price for Medpace Hldgs (MEDP)?
Medace Hldgs(MEDP)的目标价格是多少？
The latest price target for Medpace Hldgs (NASDAQ: MEDP) was reported by Baird on October 24, 2023. The analyst firm set a price target for $289.00 expecting MEDP to rise to within 12 months (a possible 17.48% upside). 6 analyst firms have reported ratings in the last year.
贝尔德公司于2023年10月24日报道了Medace Hldgs(纳斯达克代码：MEDP)的最新目标价。这家分析公司将目标价定为289.00美元，预计MEDP将在12个月内上涨(可能上涨17.48%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Medpace Hldgs (MEDP)?
Medace Hldgs(MEDP)的最新分析师评级是多少？
The latest analyst rating for Medpace Hldgs (NASDAQ: MEDP) was provided by Baird, and Medpace Hldgs upgraded their outperform rating.
贝尔德对Medace Hldgs(纳斯达克代码：MEDP)的最新分析师评级是由Baird提供的，Medace Hldgs上调了其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Medpace Hldgs (MEDP)?
Medace Hldgs(MEDP)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medpace Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medpace Hldgs was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Medace Hldgs的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Medace Hldgs的上一次评级是在2023年10月24日提交的，所以你应该预计下一次评级将在2024年10月24日左右的某个时候提供。
Is the Analyst Rating Medpace Hldgs (MEDP) correct?
分析师对Medace Hldgs(MEDP)的评级正确吗？
While ratings are subjective and will change, the latest Medpace Hldgs (MEDP) rating was a upgraded with a price target of $270.00 to $289.00. The current price Medpace Hldgs (MEDP) is trading at is $246.00, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Medace Hldgs评级被上调，目标价为270.00美元至289.00美元。目前Medace Hldgs的交易价格为246.00美元，超出了分析师的预期区间。